Freenome completed the acquisition of Oncimmune and Oncimmune Europe from Oncimmune Holdings for £13m.

Freenome, a biotechnology company with a comprehensive multiomics platform for the early detection of cancer using a standard blood draw, completed the acquisition of Oncimmune and Oncimmune Europe the subsidiaries of Oncimmune Holdings, an immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases, for £13m. "Oncimmune and Freenome share a deep commitment to patients and this acquisition is consistent with Freenome's holistic solution to cancer detection. Oncimmune's track record of translating innovative technologies into mainstream clinical use, now being integrated with Freenome's platform and team, strengthens our multiomics approach to make an even greater impact for patients across a range of indications," Mike Nolan, Freenome Chief Executive Officer.